Acusphere has been granted a US patent for its Hydrophobic Drug Delivery System (HDDS) technology for accelerating the dissolution rate of drugs.
The claims in this patent (No 6,645,528) cover porous microparticle compositions of over 150 drugs in a wide variety of therapeutic areas.
Acusphere's HDDS technology works by encapsulating very small drug particles in a dry powder porous matrix that dissolves virtually immediately upon contact with water, leaving a suspension of drug microparticles that will dissolve upon further dilution. The small size of the drug microparticles increases the surface area of the drug, promoting more rapid dissolution.
This patent includes data demonstrating that the porous microparticles that are produced using the HDDS system dissolve more rapidly than solid microparticles.
Solid drug microparticles often agglomerate without a coating, and are produced using processes that are generally regarded as cumbersome and expensive, according to Acusphere, which notes that the processes can be difficult to carry out under the aseptic conditions required for some routes of administration.
Acusphere's porous microparticles are made with a patented, single-step spray drying process that can be operated aseptically and thereby can produce microparticles for administration through diverse routes, including intravenous and oral delivery and inhalation.
The first product candidate using the HDDS technology, currently in Phase I clinical trials, is AI-850, a new formulation of cancer drug paclitaxel that currently has to be dissolved in Cremophor, a polyoxyethylated castor oil medium which can cause allergic reactions.